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Kaposi sarcoma (KS), multicentric Castleman’s disease (MCD), and plasmablastic microlymphoma, are all linked to human
herpesvirus-8 (HHV-8) infection and HIV-induced immunodeﬁciency. Herein, we describe the case of a Kenyan man diagnosed
with HIV in 2000. He deferred highly active antiretroviral therapy (HAART) and remained in good health until his CD4+
count declined in 2006. He was hospitalized with bacterial pneumonia in 2008, after which he agreed to take HAART but did
so sporadically. In 2010, he was hospitalized with fever, lymphadenopathy, pancytopenia, and an elevated HHV-8 viral load. A
lymph node biopsy showed ﬁndings consistent with KS, MCD, and plasmablastic microlymphoma. Eight months after starting
liposomal doxorubicin, Rituximab, and a new HAART regimen, he has improved clinically, and his HIV and HHV-8 viral loads
are suppressed. These three conditions, found in the same lymph node, underscore the inﬂammatory and malignant potential of
HHV-8, particularly in the milieu of HIV-induced immunodeﬁciency.
1.Introduction
I nt h ec u r r e n te r ao fh i g h l ya c t i v ea n t i r e t r o v i r a lt h e r a p y
(HAART), people infected with HIV are not only less
likely to develop AIDS-deﬁning infections, they are also
less likely to be diagnosed with an AIDS-deﬁning neoplasm
(i.e., Kaposi Sarcoma (KS) or non-Hodgkins lymphoma
(NHL)) [1–3]. As these individuals live to their sixth
decade of life and beyond, cancers associated with lifestyle
choices and aging (i.e., lung, liver, and anal carcinomas) are
increasingly important barriers to survival [4–6]. However,
AIDS-deﬁning malignancies remain a signiﬁcant cause of
morbidity and mortality for those individuals who are not
onHAARTbecausetheyare unaware oftheirHIVserostatus,
they do not have access to HAART, or they are poorly
adherent with prescribed therapies [7].
KSis etiologically linked to human herpesvirus-8 (HHV-
8 ) ,a l s ok n o w na sK S - a s s o c i a t e dh e r p e s v i r u s( K S H V )[ 8].
The HHV-8 genome contains numerous genes that code
for proteins with recognizable homology to human pro-
teins, including an interleukin-6 (IL-6) homologue [9]. IL-
6 has multiple systemic eﬀects including the support of
hematopoiesis and stimulation of B lymphocyte and plasma
cell growth. When expressed in physiologic excess, IL-6 may
contribute to dysregulation of immune responses [10].
IL-6 is also a major mediator of the systemic symptoms
associated with Castleman’s disease (CD) [11, 12]. CD is
a heterogeneous group of lymphoproliferative disorders of2 Pathology Research International
unknown etiology. Unlike unicentric CD, multicentric CD
(MCD) is strongly associated with immunosuppression and
HHV-8infection[13].PatientswithMCDfrequentlypresent
with generalized lymphadenopathy, hepatosplenomegaly,
fever, and night sweats. These debilitating systemic symp-
toms are in part due to the proinﬂammatory eﬀects of
IL-6 [14]. IL-6 also downregulates albumin production by
the liver, leading to hypoalbuminemia, which may cause
anasarca via decrease in oncotic pressure.
When comparing HIV-infected patients without MCD,
those with MCD have a 15-fold increased risk of NHL,
with the most common subtype of NHL being HHV-8-
positive plasmablastic lymphoma. Among 60 patients with
HIV and MCD, 14 were diagnosed with NHL of whom
6 (43%) had the plasmablastic variant [15]. In some
cases, the precursor to HHV8+ plasmablastic lymphoma are
the sheets of plasmablastic cells, termed microlymphomas,
found in the lymph nodes of MCD patients [15, 16]. These
microlymphomas typically express IgM with lambda light
chain restriction, but are polyclonal whereas true HHV8+
plasmablastic lymphoma is monoclonal and follows an
aggressive clinical course, responding poorly to multiagent
chemotherapy [16].
Herein, we describe the case of an HIV-infected man
with KS, MCD, and microlymphoma, all three of which
were identiﬁed within a single resected lymph node. We also
review the relevant literature with a focus on the common
etiology of these various diseases.
2.CaseReport
In 2000, a 42-year-old Kenyan man, who had sex with other
men, was diagnosed with HIV infection and neurosyphilis
while he was being evaluated for chronic sinusitis and
headache. His initial CD4+ count was 595cells/μl, and
his HIV viral load was 5,490copies/ml. Neurosyphilis was
successfullytreated,butthepatientoptedtodeferHAART.In
2003, he had unilateral and painless right thigh enlargement
and underwent surgical excision of a low-grade leiomyosar-
coma. No adjuvant treatment was recommended, and he
remained in good health for an additional two years, during
which time his CD4+ count and his HIV viral load remained
>550cells/μla n d<5,500copies/ml, respectively.
In 2006, the patient had a precipitous and persistent
fall in CD4+ count to <120cells/μl and his HIV viral load
increased to 35,000 copies/ml.However, he declinedto begin
HAART for fear of untoward medication-associated side
eﬀects. Over the next two years he lost 15 pounds, had
waxing and waning adenopathy, and was hospitalized on
one occasion with bacterial pneumonia. By June, 2008 he
had greater than 15 discrete KS lesions on his legs, his
CD4+ count was 30cells/μla n dh i sH I Vv i r a ll o a dw a s
34,000copies/ml (Figure 1).
In2009,hewashospitalized fortreatment ofmethacillin-
susceptible staphylococcus aureus pneumonia and bac-
teremia. He subsequently agreed to begin HAART, but was
poorly adherent with treatment, stopping and restarting his
HIV medications on a number of occasions.
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Figure 1: Graph of CD4+ cell counts and HIV viral loads from
2001 to 2010 plotted on a logarithmic scale showing the increase in
the viral load heralding the fall in CD4+ count, as well as showing
the drop in the viral load after the patient became compliant with
HAART.
In April 2010, he was hospitalized with intermittent
fevers, night sweats, mild pancytopenia, hypoalbuminemia,
and anasarca. A computerized tomogram (CT) of chest,
abdomen, and pelvis revealed diﬀuse but modest adenopa-
thy. He was ultimately discharged to home when assorted
cultures and special studies returned negative for an acute
infection. He was strongly encouraged to take HAART, now
consisting of darunavir, etravirine, raltegravir, and ritonavir.
One month later he was readmitted with recrudescent
fevers, palpable axillary and groin adenopathy, worsening
anasarca, and more numerous KS lesions on his neck,
trunk, and legs. Laboratory studies were notable for the
following, WBC 2400/mm3; hematocrit 24%, platelet count
48,000cells/mm3, alkaline phosphatase 409units/L (nor-
mal <150U/L), lactate dehydrogenase 636units/L (normal
<243U/L), and serum albumin 2.9g/dL, and a serum
protein electrophoresis revealed elevated globulins but no
monoclonal gammopathy. His CD4+ count was 24cells/μl,
HIV viral load 1,792copies/ml, and HHV-8 viral load was
10,000,000copies/ml. A repeat CT scan showed moderate
progression of adenopathy which was most prominent in
the axilla and retroperitoneum (Figure 2). An axillary lymph
node was biopsied and showed changes in keeping with
MCD. In addition, numerous B cell follicles contained broad
mantle zones with numerous larger plasmablastic cells that
formed microscopic clusters and sheets within the germinal
centers and in the interfollicular areas. These plasmablastic
cells expressed HHV-8 and lambda light chain consistent
with so-called microlymphoma, which was supported by
additionalstudies.AfocusofHHV-8positiveKSspindlecells
was also identiﬁed (Figures 3(a)–3(d)).Pathology Research International 3
Figure 2: Coronal computerized tomograms of chest, abdomen, and pelvis with arrows highlighting foci of axillary and retroperitoneal
adenopathy.
(a) (b)
(c) (d)
Figure 3: (a) H&E at 200x, illustrating typical Kaposi sarcoma morphology, (b) 100x of residual follicle with plasma cells, plasmablasts and
mixed inﬂammation,(c) lambda light chain immunohistochemistry (IHC) at 100x, D) kappa light chain IHC at 100x.
The patient, now age 52, began treatment consisting
of liposomal doxorubicin (20mg/m2 every 14 days) in
conjunction with Rituximab (375mg /m2 weekly times four)
and concurrent HAART consisting of the same regimen
listed above. More aggressive treatment with multiagent
chemotherapy was not given since the patient had only
premalignant plasmablastic microlymphoma, and not frank
HHV8+ plasmablastic lymphoma, and MCD and KS have
been shown to respond to this more conservative treatment.
At eight-months followup, anasarca had resolved and he
had regained lost weight. Cutaneous KS was less prominent,
and a CT scan showed diminished adenopathy. Laboratory
studies are now notable for a gradual improvement in
complete blood count, hepatic transaminases, and alkaline
phosphatase. His serum albumin has returned to normal, his
HIV viral load is nondetectable; although, his CD4+ count
remains <50cells/μL,andhisHHV-8viralloadhasdecreased
by greater than two orders of magnitude.4 Pathology Research International
3.Discussion
ThethreeseparateconditionsofKS,MCD,andplasmablastic
microlymphoma, all identiﬁed within a single lymph node
biopsy in a patient with AIDS, underscore the diverse
malignant and inﬂammatory potential of HHV-8 infection,
especially in the milieu of decreased cellular immunity due
to HIV infection.
HHV-8 is a member of the gammaherpesvirus family
and shows 40% sequence homology with the oncogenic
Epstein-Barr virus [17]. Like other herpesviruses, HHV-8
is adept at evading the immune system through its ability
to use viral immunomodulators that interfere with the host
immune response, many ofwhich are homologuesof human
genes [18]. One way HHV-8 evades the immune system is
through the skewing of the host immune response from Th1
to Th2, in part accomplished by the action of viral-IL-6
(vIL-6). This homologue of human IL-6 acts through gp130
to promote Th2-cell development and responsiveness, while
also inhibiting Th1-cell responses [19]. HHV-8 also encodes
proteins that interact with the host immune system to
inhibitcomplementanddown regulatethe adaptiveimmune
response.
The oncogenic potential of HHV-8 is, in part, due to
its ability to cause chromosomal instability, to alter gene
expression, to increase telomerase activity, and, promote cell
invasiveness, proliferation, and survival [20]. The latency-
associated nuclear antigen (LANA) inhibits p53-induced
apoptosis while also inactivating the retinoblastoma gene,
which would otherwise inhibit progression through theG1/S
cell cycle checkpoint [21, 22]. vIL-6 can activate multiple
cellularpathways,includingJAK/STAT,whichinturnleadsto
vascular endothelial growth factor expression and signaling
[23]. When vIL-6-expressing ﬁbroblasts are injected into
mice, highly vascular tumor formation, hematopoiesis, and
plasmacytosis take place [24] .O t h e rv i r a lg e n e sc o d ef o r
proteins that are also implicated in oncogenesis: viral
interferonregulatory factor-1(v-IRF-1)suppressesbothtype
I and type II interferon responses; K13 (aka vFLIP) inhibits
Fas-mediated apoptosis; viral g-protein-coupled receptor
(vGPCR), a homologue of the IL-8 receptor, produces
tumors when vGPCR-expressing ﬁbroblasts are injected into
nude mice [25–28].
Since Chang and colleagues ﬁrst identiﬁed HHV-8 in KS
tissue from HIV seropositive patients, our understanding of
the pathophysiology of various HHV-8-associated diseases
has grown substantially [29]. HHV-8 is now etiologically
linked to KS in HIV-infected patients, as well as KS
in immunocompetent patients (classic KS) [30]. More
recently, HHV-8 has been associated with MCD, HHV8+
plasmablastic lymphoma, primary eﬀusion lymphoma, and
germinotrophic lymphoproliferative disorders [31–33].
HIV-seropositive individuals with MCD have a signiﬁ-
cantly greater risk of NHL than their HIV-negative counter-
parts. In MCD, HHV-8 is speciﬁcally associated with mono-
typic (IgM λ) but polyclonal HHV-8+ plasmablasts which
occur as isolated clusters of cells in the mantle zone of B-cell
follicles, called microlymphomas [34, 35]. The expansion of
these plasmablastic microlymphomas from MCD lesions to
aggressive NHL is probably triggered by a second oncogenic
event.This implies that MCD,microlymphoma and HHV8+
plasmablastic lymphoma represent three stages of a single
disease in the backdrop of HIV-induced immunodeﬁciency.
The speciﬁc NHL implicated in this process, HHV-8+
plasmablastic lymphoma, is a rare, aggressive B-cell lym-
phoma with a poor prognosis [36]. In an abstract regarding
131 patients with AIDS-associated plasmablastic lymphoma,
death occurred in 59% of patients with a median survival of
only 14 months from diagnosis [37]. However, only 16% of
those 131 cases were HHV-8+, and these were later excluded
from the ﬁnal, peer-reviewed publication [38], highlighting
the fact that the HHV-8+ form of plasmablastic lymphoma
is distinct from the more common plasmablastic lymphoma,
which is more frequently associated with Epstein-Barr virus
and often presents as skin or oropharyngeal nodules. The
distinction between these diﬀerent forms of plasmablastic
lymphoma, and any possible diﬀerences in clinical course
and response to treatment, is an area where further research
is needed.
Coexistence of MCD and KS in the same tissue is a
common phenomenon. Among 24 lymph nodes, 15 (63%)
showed evidence of coexisting KS [39]. The association may
beduetolyticHHV-8infectionofB-lymphoidcellsexposing
susceptible endothelialcells atvulnerable sites. Disregulation
of IL-6 in HHV-8-infected cells is not only a major trigger
for disease in the angiofollicular hyperplasia of MCD, and
KS, it is also a major trigger for disease progression in HHV-
8 plasmablastic and primary eﬀusion lymphomas.
While the overall median survival of patients with
AIDS and coexistent MCD and NHL is generally just a
few months, there are exceptions [40, 41]. Horster and
colleagues describe the case of a patient with AIDS, MCD
and plasmablastic leukemiawho was treated with multiagent
chemotherapy, splenectomy, and maintenance thalidomide
and who was still alive at a 28-month followup [42].
Another patient with AIDS and MCD had a plasmablastic
lymphoma of the spermatic cord. He too was treated with
multiagent chemotherapy, and despite a subsequent relapse
of MCD he was alive at an 11-month followup [43]. Given
recent successes associated with treating patients with HIV-
associated MCD with antivirals, and the better outcome
associated with treating AIDS-related lymphoma patients
with modern supportive care in conjunction with HAART,
rituximab, and when needed, chemotherapy, we are hopeful
that the prospects of HIV-infected patients with HHV-8-
associated plasmablastic lymphoma, KS, and MCD will also
improve [44, 45].
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